BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tong Z, Kunnumakkara AB, Wang H, Matsuo Y, Diagaradjane P, Harikumar KB, Ramachandran V, Sung B, Chakraborty A, Bresalier RS. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res. 2008;68:6100-6108. [PMID: 18676832 DOI: 10.1158/0008-5472.can-08-0540] [Cited by in Crossref: 104] [Cited by in F6Publishing: 59] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Lelièvre P, Sancey L, Coll JL, Deniaud A, Busser B. Iron Dysregulation in Human Cancer: Altered Metabolism, Biomarkers for Diagnosis, Prognosis, Monitoring and Rationale for Therapy. Cancers (Basel) 2020;12:E3524. [PMID: 33255972 DOI: 10.3390/cancers12123524] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
2 Chen W, Ayala-Orozco C, Biswal NC, Perez-Torres C, Bartels M, Bardhan R, Stinnet G, Liu XD, Ji B, Deorukhkar A, Brown LV, Guha S, Pautler RG, Krishnan S, Halas NJ, Joshi A. Targeting pancreatic cancer with magneto-fluorescent theranostic gold nanoshells. Nanomedicine (Lond) 2014;9:1209-22. [PMID: 24063415 DOI: 10.2217/nnm.13.84] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
3 Kaur S, Chakraborty S, Baine MJ, Mallya K, Smith LM, Sasson A, Brand R, Guha S, Jain M, Wittel U, Singh SK, Batra SK. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. PLoS One. 2013;8:e55171. [PMID: 23383312 DOI: 10.1371/journal.pone.0055171] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
4 Li T, Yu L, Wen J, Liao Q, Liu Z. An early-screening biomarker of endometrial carcinoma: NGAL is associated with epithelio-mesenchymal transition. Oncotarget 2016;7:86064-74. [PMID: 27863382 DOI: 10.18632/oncotarget.13340] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Santiago-Sánchez GS, Pita-Grisanti V, Quiñones-Díaz B, Gumpper K, Cruz-Monserrate Z, Vivas-Mejía PE. Biological Functions and Therapeutic Potential of Lipocalin 2 in Cancer. Int J Mol Sci 2020;21:E4365. [PMID: 32575507 DOI: 10.3390/ijms21124365] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
6 Sanegre S, Eritja N, de Andrea C, Diaz-Martin J, Diaz-Lagares Á, Jácome MA, Salguero-Aranda C, García Ros D, Davidson B, Lopez R, Melero I, Navarro S, Ramon Y Cajal S, de Alava E, Matias-Guiu X, Noguera R. Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma. Front Cell Dev Biol 2021;9:670185. [PMID: 34150764 DOI: 10.3389/fcell.2021.670185] [Reference Citation Analysis]
7 Sun Y, Yokoi K, Li H, Gao J, Hu L, Liu B, Chen K, Hamilton SR, Fan D, Sun B, Zhang W. NGAL expression is elevated in both colorectal adenoma-carcinoma sequence and cancer progression and enhances tumorigenesis in xenograft mouse models. Clin Cancer Res 2011;17:4331-40. [PMID: 21622717 DOI: 10.1158/1078-0432.CCR-11-0226] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
8 Chiang KC, Yeh TS, Wu RC, Pang JS, Cheng CT, Wang SY, Juang HH, Yeh CN. Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker. Sci Rep 2016;6:36138. [PMID: 27782193 DOI: 10.1038/srep36138] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
9 Scaggiante B, Kazemi M, Pozzato G, Dapas B, Farra R, Grassi M, Zanconati F, Grassi G. Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials. World J Gastroenterol 2014; 20(5): 1268-1288 [PMID: 24574801 DOI: 10.3748/wjg.v20.i5.1268] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 51] [Article Influence: 7.0] [Reference Citation Analysis]
10 Gumpper K, Dangel AW, Pita-Grisanti V, Krishna SG, Lara LF, Mace T, Papachristou GI, Conwell DL, Hart PA, Cruz-Monserrate Z. Lipocalin-2 expression and function in pancreatic diseases. Pancreatology 2020;20:419-24. [PMID: 31932215 DOI: 10.1016/j.pan.2020.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Chiang KC, Yeh TS, Huang CC, Chang YC, Juang HH, Cheng CT, Pang JS, Hsu JT, Takano M, Chen TC, Kittaka A, Hsiao M, Yeh CN. MART-10 represses cholangiocarcinoma cell growth and high vitamin D receptor expression indicates better prognosis for cholangiocarcinoma. Sci Rep 2017;7:43773. [PMID: 28256614 DOI: 10.1038/srep43773] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Che K, Han W, Zhang M, Niu H. Role of neutrophil gelatinase-associated lipocalin in renal cell carcinoma. Oncol Lett 2021;21:148. [PMID: 33552266 DOI: 10.3892/ol.2020.12409] [Reference Citation Analysis]
13 Brown RAM, Richardson KL, Kabir TD, Trinder D, Ganss R, Leedman PJ. Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology. Front Oncol 2020;10:476. [PMID: 32328462 DOI: 10.3389/fonc.2020.00476] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 25.0] [Reference Citation Analysis]
14 Eibl G, Rozengurt E. Obesity and Pancreatic Cancer: Insight into Mechanisms. Cancers (Basel) 2021;13:5067. [PMID: 34680216 DOI: 10.3390/cancers13205067] [Reference Citation Analysis]
15 Bauvois B, Susin SA. Revisiting Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Cancer: Saint or Sinner? Cancers (Basel) 2018;10:E336. [PMID: 30231474 DOI: 10.3390/cancers10090336] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
16 Yang J, Moses MA. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle 2009;8:2347-52. [PMID: 19571677 DOI: 10.4161/cc.8.15.9224] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 7.4] [Reference Citation Analysis]
17 Wu BL, Li CQ, Du ZP, Zhou F, Xie JJ, Luo LW, Wu JY, Zhang PX, Xu LY, Li EM. Functional analysis of the mRNA profile of neutrophil gelatinase‑associated lipocalin overexpression in esophageal squamous cell carcinoma using multiple bioinformatic tools. Mol Med Rep 2014;10:1800-12. [PMID: 25109818 DOI: 10.3892/mmr.2014.2465] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
18 Candido S, Maestro R, Polesel J, Catania A, Maira F, Signorelli SS, McCubrey JA, Libra M. Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget 2014;5:1576-94. [PMID: 24742531 DOI: 10.18632/oncotarget.1738] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 9.7] [Reference Citation Analysis]
19 Pedersen KS, Bamlet WR, Oberg AL, de Andrade M, Matsumoto ME, Tang H, Thibodeau SN, Petersen GM, Wang L. Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls. PLoS One. 2011;6:e18223. [PMID: 21455317 DOI: 10.1371/journal.pone.0018223] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 5.9] [Reference Citation Analysis]
20 Mir SU, Jin L, Craven RJ. Neutrophil gelatinase-associated lipocalin (NGAL) expression is dependent on the tumor-associated sigma-2 receptor S2RPgrmc1. J Biol Chem 2012;287:14494-501. [PMID: 22418433 DOI: 10.1074/jbc.M111.324921] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
21 Wang Y, Zeng T. Neutrophil gelatinase-associated lipocalin protein as a biomarker in the diagnosis of breast cancer: A meta-analysis. Biomed Rep 2013;1:479-83. [PMID: 24648972 DOI: 10.3892/br.2013.89] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
22 Winter JM, Tang LH, Klimstra DS, Brennan MF, Brody JR, Rocha FG, Jia X, Qin LX, D'Angelica MI, DeMatteo RP, Fong Y, Jarnagin WR, O'Reilly EM, Allen PJ. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One 2012;7:e40157. [PMID: 22792233 DOI: 10.1371/journal.pone.0040157] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 8.1] [Reference Citation Analysis]
23 Huang DY, Dai ZR, Li WM, Wang RG, Yang SM. Inhibition of EGF expression and NF-κB activity by treatment with quercetin leads to suppression of angiogenesis in nasopharyngeal carcinoma. Saudi J Biol Sci 2018;25:826-31. [PMID: 29740251 DOI: 10.1016/j.sjbs.2016.11.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
24 Harati MD, Amiri F, Jaleh F, Mehdipour A, Harati MD, Molaee S, Bahadori M, Shokrgozar MA, Jalili MA, Roudkenar MH. Targeting delivery of lipocalin 2-engineered mesenchymal stem cells to colon cancer in order to inhibit liver metastasis in nude mice. Tumour Biol. 2015;36:6011-6018. [PMID: 25740061 DOI: 10.1007/s13277-015-3277-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
25 Yang J, McNeish B, Butterfield C, Moses MA. Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J 2013;27:45-50. [PMID: 22982376 DOI: 10.1096/fj.12-211730] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 7.1] [Reference Citation Analysis]
26 Chung IH, Chen CY, Lin YH, Chi HC, Huang YH, Tai PJ, Liao CJ, Tsai CY, Lin SL, Wu MH, Chen CY, Lin KH. Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer. Oncotarget 2015;6:15050-64. [PMID: 25940797 DOI: 10.18632/oncotarget.3670] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
27 Lourdusamy V, Tharian B, Navaneethan U. Biomarkers in bile-complementing advanced endoscopic imaging in the diagnosis of indeterminate biliary strictures. World J Gastrointest Endosc 2015; 7(4): 308-317 [PMID: 25901209 DOI: 10.4253/wjge.v7.i4.308] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
28 Chakraborty S, Kaur S, Guha S, Batra SK. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta. 2012;1826:129-169. [PMID: 22513004 DOI: 10.1016/j.bbcan.2012.03.008] [Cited by in Crossref: 124] [Cited by in F6Publishing: 205] [Article Influence: 13.8] [Reference Citation Analysis]
29 Feng M, Feng J, Chen W, Wang W, Wu X, Zhang J, Xu F, Lai M. Lipocalin2 suppresses metastasis of colorectal cancer by attenuating NF-κB-dependent activation of snail and epithelial mesenchymal transition. Mol Cancer 2016;15:77. [PMID: 27912767 DOI: 10.1186/s12943-016-0564-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
30 Bouchet S, Bauvois B. Neutrophil Gelatinase-Associated Lipocalin (NGAL), Pro-Matrix Metalloproteinase-9 (pro-MMP-9) and Their Complex Pro-MMP-9/NGAL in Leukaemias. Cancers (Basel). 2014;6:796-812. [PMID: 24713998 DOI: 10.3390/cancers6020796] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
31 Perego S, Sansoni V, Ziemann E, Lombardi G. Another Weapon against Cancer and Metastasis: Physical-Activity-Dependent Effects on Adiposity and Adipokines. Int J Mol Sci 2021;22:2005. [PMID: 33670492 DOI: 10.3390/ijms22042005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Brown LJ, Alawoki M, Crawford ME, Reida T, Sears A, Torma T, Albig AR. Lipocalin-7 is a matricellular regulator of angiogenesis. PLoS One 2010;5:e13905. [PMID: 21085487 DOI: 10.1371/journal.pone.0013905] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
33 Bolós V, Gasent JM, López-Tarruella S, Grande E. The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther 2010;3:83-97. [PMID: 20616959 DOI: 10.2147/ott.s6909] [Cited by in Crossref: 104] [Cited by in F6Publishing: 76] [Article Influence: 9.5] [Reference Citation Analysis]
34 Verma M, Dahiya K, Soni A, Dhankhar R, Ghalaut VS, Bansal A, Kaushal V. Levels of neutrophil gelatinase-assosciated lipocalin in patients with head and neck squamous cell carcinoma in Indian population from Haryana state. World J Clin Oncol 2017; 8(3): 261-265 [PMID: 28638796 DOI: 10.5306/wjco.v8.i3.261] [Reference Citation Analysis]
35 Lu KH, Yang JS, Hsieh YH, Chu HJ, Chou CH, Lu EW, Lin CW, Yang SF. Lipocalin-2 Inhibits Osteosarcoma Cell Metastasis by Suppressing MET Expression via the MEK-ERK Pathway. Cancers (Basel) 2021;13:3181. [PMID: 34202288 DOI: 10.3390/cancers13133181] [Reference Citation Analysis]
36 Sanchis-Gomar F, Lippi G. Physical activity - an important preanalytical variable. Biochem Med (Zagreb) 2014;24:68-79. [PMID: 24627716 DOI: 10.11613/BM.2014.009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 4.9] [Reference Citation Analysis]
37 Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao HL, Li H, Zhang SR, Xu JZ, Qi ZH, Ni QX, Yu XJ, Liu L. Angiogenesis in pancreatic cancer: current research status and clinical implications. Angiogenesis 2019;22:15-36. [PMID: 30168025 DOI: 10.1007/s10456-018-9645-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 16.7] [Reference Citation Analysis]
38 Mannelqvist M, Stefansson IM, Wik E, Kusonmano K, Raeder MB, Øyan AM, Kalland KH, Moses MA, Salvesen HB, Akslen LA. Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer 2012;12:169. [PMID: 22559235 DOI: 10.1186/1471-2407-12-169] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
39 Miki M, Oono T, Fujimori N, Takaoka T, Kawabe K, Miyasaka Y, Ohtsuka T, Saito D, Nakamura M, Ohkawa Y, Oda Y, Suyama M, Ito T, Ogawa Y. CLEC3A, MMP7, and LCN2 as novel markers for predicting recurrence in resected G1 and G2 pancreatic neuroendocrine tumors. Cancer Med 2019;8:3748-60. [PMID: 31129920 DOI: 10.1002/cam4.2232] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
40 Nuntagowat C, Leelawat K, Tohtong R. NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation. Clin Exp Metastasis. 2010;27:295-305. [PMID: 20373132 DOI: 10.1007/s10585-010-9327-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
41 Leung L, Radulovich N, Zhu CQ, Organ S, Bandarchi B, Pintilie M, To C, Panchal D, Tsao MS. Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma. PLoS One 2012;7:e46677. [PMID: 23056397 DOI: 10.1371/journal.pone.0046677] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
42 Hu C, Yang K, Li M, Huang W, Zhang F, Wang H. Lipocalin 2: a potential therapeutic target for breast cancer metastasis. Onco Targets Ther 2018;11:8099-106. [PMID: 30519052 DOI: 10.2147/OTT.S181223] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
43 Chan YR, Liu JS, Pociask DA, Zheng M, Mietzner TA, Berger T, Mak TW, Clifton MC, Strong RK, Ray P, Kolls JK. Lipocalin 2 is required for pulmonary host defense against Klebsiella infection. J Immunol 2009;182:4947-56. [PMID: 19342674 DOI: 10.4049/jimmunol.0803282] [Cited by in Crossref: 147] [Cited by in F6Publishing: 139] [Article Influence: 12.3] [Reference Citation Analysis]
44 Lipinski M, Degowska M, Rydzewska G. Cystic fluid neutrophil gelatinase-associated lipocalin (NGAL) concentration in differential diagnosis of pancreatic cystic lesions: a new factor enters the scene? Prz Gastroenterol 2018;13:132-6. [PMID: 30002772 DOI: 10.5114/pg.2017.68805] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
45 Hsu MY, Mina E, Roetto A, Porporato PE. Iron: An Essential Element of Cancer Metabolism. Cells 2020;9:E2591. [PMID: 33287315 DOI: 10.3390/cells9122591] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
46 Song S, Ji B, Ramachandran V, Wang H, Hafley M, Logsdon C, Bresalier RS. Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signalling. PLoS One. 2012;7:e42699. [PMID: 22900040 DOI: 10.1371/journal.pone.0042699] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 7.7] [Reference Citation Analysis]
47 Hsieh YH, Tsai JP, Yu CL, Lee CC, Hsu JC, Chen JC. Overexpression of Lipocalin-2 Inhibits Proliferation and Invasiveness of Human Glioblastoma Multiforme Cells by Activating ERK Targeting Cathepsin D Expression. Biology (Basel) 2021;10:390. [PMID: 34062746 DOI: 10.3390/biology10050390] [Reference Citation Analysis]
48 Gomez-Chou SB, Swidnicka-Siergiejko AK, Badi N, Chavez-Tomar M, Lesinski GB, Bekaii-Saab T, Farren MR, Mace TA, Schmidt C, Liu Y, Deng D, Hwang RF, Zhou L, Moore T, Chatterjee D, Wang H, Leng X, Arlinghaus RB, Logsdon CD, Cruz-Monserrate Z. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. Cancer Res 2017;77:2647-60. [PMID: 28249896 DOI: 10.1158/0008-5472.CAN-16-1986] [Cited by in Crossref: 49] [Cited by in F6Publishing: 32] [Article Influence: 12.3] [Reference Citation Analysis]
49 Kaur S, Sharma N, Krishn SR, Lakshmanan I, Rachagani S, Baine MJ, Smith LM, Lele SM, Sasson AR, Guha S, Mallya K, Anderson JM, Hollingsworth MA, Batra SK. MUC4-mediated regulation of acute phase protein lipocalin 2 through HER2/AKT/NF-κB signaling in pancreatic cancer. Clin Cancer Res 2014;20:688-700. [PMID: 24240113 DOI: 10.1158/1078-0432.CCR-13-2174] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
50 Molina L, Bell D, Tao J, Preziosi M, Pradhan-Sundd T, Singh S, Poddar M, Luo J, Ranganathan S, Chikina M, Monga SP. Hepatocyte-Derived Lipocalin 2 Is a Potential Serum Biomarker Reflecting Tumor Burden in Hepatoblastoma. Am J Pathol 2018;188:1895-909. [PMID: 29920228 DOI: 10.1016/j.ajpath.2018.05.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
51 Harikumar KB, Kunnumakkara AB, Ochi N, Tong Z, Deorukhkar A, Sung B, Kelland L, Jamieson S, Sutherland R, Raynham T, Charles M, Bagherzadeh A, Foxton C, Boakes A, Farooq M, Maru D, Diagaradjane P, Matsuo Y, Sinnett-Smith J, Gelovani J, Krishnan S, Aggarwal BB, Rozengurt E, Ireson CR, Guha S. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther. 2010;9:1136-1146. [PMID: 20442301 DOI: 10.1158/1535-7163.mct-09-1145] [Cited by in Crossref: 102] [Cited by in F6Publishing: 86] [Article Influence: 9.3] [Reference Citation Analysis]
52 Chung IH, Wu TI, Liao CJ, Hu JY, Lin YH, Tai PJ, Lai CH, Lin KH. Overexpression of lipocalin 2 in human cervical cancer enhances tumor invasion. Oncotarget 2016;7:11113-26. [PMID: 26840566 DOI: 10.18632/oncotarget.7096] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
53 Tong Z, Chakraborty S, Sung B, Koolwal P, Kaur S, Aggarwal BB, Mani SA, Bresalier RS, Batra SK, Guha S. Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells. Cancer 2011;117:2408-18. [PMID: 24048788 DOI: 10.1002/cncr.25803] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
54 Li C, Li Y, Lou L, Han X, Wang H, Huang T, Li C. The interaction between lipocalin 2 and dipyridine ketone hydrazone dithiocarbamte may influence respective function in proliferation and metastasis-related gene expressions in HepG2 cell. J Biol Inorg Chem 2021;26:123-33. [PMID: 33449164 DOI: 10.1007/s00775-020-01842-8] [Reference Citation Analysis]
55 Wang R, Asangani IA, Chakravarthi BV, Ateeq B, Lonigro RJ, Cao Q, Mani RS, Camacho DF, McGregor N, Schumann TE, Jing X, Menawat R, Tomlins SA, Zheng H, Otte AP, Mehra R, Siddiqui J, Dhanasekaran SM, Nyati MK, Pienta KJ, Palanisamy N, Kunju LP, Rubin MA, Chinnaiyan AM, Varambally S. Role of transcriptional corepressor CtBP1 in prostate cancer progression. Neoplasia 2012;14:905-14. [PMID: 23097625 DOI: 10.1593/neo.121192] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
56 Albini A, Indraccolo S, Noonan DM, Pfeffer U. Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs. Clin Exp Metastasis 2010;27:419-39. [PMID: 20383568 DOI: 10.1007/s10585-010-9312-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
57 Srisomsap C, Sawangareetrakul P, Subhasitanont P, Chokchaichamnankit D, Chiablaem K, Bhudhisawasdi V, Wongkham S, Svasti J. Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes. J Biomed Biotechnol 2010;2010:437143. [PMID: 20069059 DOI: 10.1155/2010/437143] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
58 Lee S, Kim JH, Kim JH, Seo JW, Han HS, Lee WH, Mori K, Nakao K, Barasch J, Suk K. Lipocalin-2 Is a chemokine inducer in the central nervous system: role of chemokine ligand 10 (CXCL10) in lipocalin-2-induced cell migration. J Biol Chem 2011;286:43855-70. [PMID: 22030398 DOI: 10.1074/jbc.M111.299248] [Cited by in Crossref: 94] [Cited by in F6Publishing: 64] [Article Influence: 9.4] [Reference Citation Analysis]
59 Matsuo Y, Sawai H, Ochi N, Yasuda A, Sakamoto M, Takahashi H, Funahashi H, Takeyama H, Guha S. Proteasome inhibitor MG132 inhibits angiogenesis in pancreatic cancer by blocking NF-kappaB activity. Dig Dis Sci 2010;55:1167-76. [PMID: 19399612 DOI: 10.1007/s10620-009-0814-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]